Skip to main content
. 2013 May;68(5):652–657. doi: 10.6061/clinics/2013(05)12

Figure 1.

Figure 1

1) Cytoplasmic and nuclear immunoexpression of BUB1 in localized prostate cancer (A and B), in lymph node metastases (C), and in bone metastases (D). 2) Nuclear immunoexpression of c-C-MYC in localized prostate cancer (A and B), in lymph node metastases (C), and in bone metastases (D). 3) Nuclear (A) and cytoplasmic (B) immunoexpression of RAS in localized prostate cancer, in lymph node metastases (C), and in bone metastases (D). 4) Nuclear immunoexpression of RB in normal prostate glands (A), in localized prostate cancer (B), in lymph node metastases (C), and in bone metastases (D). 5) Nuclear immunoexpression of SMARCA5 in localized prostate cancer (A and B), in lymph node metastases (C), and in bone metastases (D). 6) Immunoexpression of LAMB3 in the basal membrane (A) and cytoplasmic staining in localized prostate cancer (B), in lymph node metastases (C), and in bone metastases (D). 7) Nuclear Ki-67 immunoexpression in localized prostate cancer (A), in the lymph node (B), and in bone metastasis (C).